Glycomimetics

GlycoMimetics is a late-stage biotechnology company based in the United States that focuses on developing glycobiology-based therapies for cancers and inflammatory diseases. The company has approximately 11 employees and its lead candidate, uproleselan, is in pivotal phase 3 development for relapsed/refractory acute myeloid leukemia.